Delivery Order SPE2DB20D1100-SPE2DB25FD7M5
Award Date 7/30/25
Potential Completion Date 7/31/25
Potential Value $1.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $2,446.62 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 31, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a recently approved diabetes and weight management...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens valued at $14,691.86. This firm fixed-price delivery order, issued on August 13, 2025, with completion expected by August 14, 2025, represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound 10 mg/0.5 ml pens in 0.5 ml quantities, valued at $14,093.41. This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $2,669.05 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a prescription medication used in diabetes and weight management treatment, and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,332.51 on August 13, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens. This competitively awarded, firm fixed-price delivery order is non-set-aside and is scheduled for completion by August 14, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management,...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $12,414.97 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management in patients with obesity or overweight conditions,...